Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2009, Pages 526-532

  Chuchalin, Alexander ^a   Amelina, Elena ^a   Bianco, Federico ^b  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Cystic fibrosis; Efficacy; Inhaled tobramycin; Pharmacoeconomics; Pharmacokinetics; Tolerability

Indexed keywords

BRAMITOB; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HOSPITALIZATION; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; NEPHROTOXICITY; NUTRITIONAL STATUS; OSMOLARITY; OTOTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUALITY OF LIFE; SIDE EFFECT; SPUTUM ANALYSIS; TINNITUS; VOICE CHANGE;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; HUMANS; NUTRITIONAL STATUS; PATIENT COMPLIANCE; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TOBRAMYCIN;

EID: 71249122266     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.06.001     Document Type: Article

References (45)

1. Döring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Høiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
2. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989) 1066-1073
3. Zielenski J., Rozmahel R., Bozon D., Kerem B., Grzelczak Z., Riordan J.R., et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 10 (1991) 214-228
4. Milla C.E. Nutrition and lung disease in cystic fibrosis. Clin Chest Med 28 (2007) 319-330
5. Cystic FibrosisFoundation: Patient Registry 2005 Annual Report. Bethesda, Maryland; 2005.
6. Cystic Fibrosis Foundation. Patient Registry Annual Report, Bethesda, Maryland; 1996.
7. Gibson R.L., Emerson J., McNamara S., Burns J.L., Rosenfeld M., Yunker A., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167 (2003) 841-849
8. Cooney G.F., Lum B.L., Tomaselli M., and Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 34 (1994) 255-259
9. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., and Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122 (2002) 219-226
10. Knowles M.R., Robinson J.M., Wood R.E., Pue C.A., Mentz W.M., Wager G.C., et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J Clin Invest 100 (1997) 2588-2595
11. Dolovich M.B. Assessing nebulizer performance. Respir Care 47 (2002) 1290-1301 discussion 1301-1304
12. ®. Pediatr Drugs 9 (2007) 3-9
13. ® (inhaled tobramycin 300 mg/4 ml) with next generation nebulisers (2007), Congress of the Italian Cystic Fibrosis Society
14. ® rapid or PARI LC PIusTM nebulizers in cystic fibrosis patients. J Cyst Fibros 6 Suppl 1 (2007) S12 [abstract A050 and poster]
15. Geller D.E., Rosenfeld M., Waltz D.A., Wilmott R.W., and the AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 123 (2003) 28-36
16. Mendelman P.M., Smith A.L., Levy J., Weber A., Ramsey B., and Davis R.L. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 132 (1985) 761-765
17. Høiby N., Frederiksen B., and Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4 Suppl 2 (2005) 49-54
18. Gibson R.L., Emerson J., Mayer-Hamblett N., Burns J.L., McNamara S., Accurso F.J., et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 42 (2007) 610-623
19. Ramsey B.W., Dorkin H.L., Eisenberg J.D., Gibson R.L., Harwood I.R., Kravitz R.M., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. New Engl J Med 328 (1993) 1740-1746
20. Lenoir G., Antypkin Y.G., Miano A., Moretti P., Zanda M., Varoli G., et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs 9 (2007) 11-20
21. Hodson M.E., Gallagher C.G., and Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20 (2002) 658-664
22. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. New Engl J Med 340 (1999) 23-30
23. ®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr Drugs 9 (2007) 21-31
24. Kerem E., Reisman J., Corey M., Canny G.J., and Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326 (1992) 1187-1191
25. Ramsey B.W., and Boat T.F. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 124 (1994) 177-192
26. Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 120 (2001) 107S-113S
27. Marostica P.J., Weist A.D., Eigen H., Angelicchio C., Christoph K., Savage J., et al. Spirometry in 3- to 6-year-old children with cystic fibrosis. Am J Respir Crit Care Med 166 (2002) 67-71
28. Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121 (2002) 55-63
29. Anderson G.G., Moreau-Marquis S., Stanton B.A., and O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76 (2008) 1423-1433
30. Burns J.L., Van Dalfsen J.M., Shawar R.M., Otto K.L., Garber R.L., Quan J.M., et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179 (1999) 1190-1196
31. Murphy T.D., Anbar R.D., Lester L.A., Nasr S.Z., Nickerson B., VanDevanter D.R., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 38 (2004) 314-320
32. Iles R., Legh-Smith J., Drummond M., Prevost A., and Vowler S. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibros 2 (2003) 120-128
33. Restrepo R.D., Alvarez M.T., Wittnebel L.D., Sorenson H., Wettstein R., Vines D.L., et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 3 (2008) 371-384
34. Weiner J.R., Toy E.L., Sacco P., and Duh M.S. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother 9 (2008) 751-766
35. Quittner A.L., and Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 33 (2002) 269-276
36. Hill DM, Fukushima LK, Hsu E, Woo MS. Obstacles to use of high-dose aerosolized tobramycin in eligible cystic fibrosis patients. American Thoracic Society International Conference, 2005.
37. LeLorier J., Perreault S., Birnbaum H., Greenberg P., and Sheehy O. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clin Ther 22 (2000) 140-151
38. Courtney J.M., Bradley J., Mccaughan J., O'Connor T.M., Shortt C., Bredin C.P., et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 42 (2007) 525-532
39. Stern M., Wiedemann B., Wenzlaff P., and the German Cystic Fibrosis Quality Assessment Group. From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995-2006. Eur Respir J 31 (2008) 29-35
40. Lamb H.M., and Goa K.L. Management of patients with cystic fibrosis: defining the role of inhaled tobramycin. Dis Manage Health Outcomes 6 (1999) 93-108
41. Nikolaizik W.H., Trociewicz K., and Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 20 (2002) 122-126
42. Ramagopal M., and Lands L.C. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulmonol 29 (2000) 366-370
43. AHFS drug information. Tobramycin sulfate (2006). http://www.ashp.org/ahfs/first_rel/Revised-tobramycin_oct2006.pdf [accessed 1.11.07]
44. Modi A.C., and Quittner A.L. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way?. J Pediatr Psychol 31 (2006) 846-858
45. Modi A.C., Lim C.S., Yu N., Geller D., Wagner M.H., and Quittner A.L. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 5 (2006) 177-185